Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 13/20 | 0.66 |
| ▸ | ABL1 | P00519 | 12/20 | 0.66 |
| ▸ | BCR | P11274 | 8/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.66 |
| ▸ | PRKCA | P17252 | 2/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 8/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | ABL2 | P42684 | 1/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903621 | 0.90 | PDGFRA (0.82) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4897274 | 0.89 | PDGFRA (0.80) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL6041138 | 0.89 | PDGFRA (0.62) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4900883 | 0.88 | PDGFRA (0.81) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4899602 | 0.88 | PDGFRA (0.82) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4899621 | 0.87 | PDGFRA (0.57) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4892512 | 0.86 | ABL1 (0.67) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4903235 | 0.86 | PDGFRA (0.63) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4900320 | 0.86 | PDGFRA (0.58) | PDGFRAABL1BCRPDGFRBPRKCA | |
| SCHEMBL4905638 | 0.86 | PDGFRA (0.67) | PDGFRAABL1BCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2586/4885ABL1 901/4885BCR 1338/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | PDGFRA 2913/4885ABL1 904/4885BCR 1230/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | PDGFRA 373/4885ABL1 2843/4885BCR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.